Posted on 21/05/2009 in Pharmaceutical Company Financials Novartis has signed an agreement to acquire Ebewe Pharma for 925 million euros.
As well as helping the business expand, the deal will provide the former's pharmaceutical division Sandoz with the chance to improve patient access to generic oncology medicines.
Carboplatin, methotrexate, epirubicin and paclitaxel are all examples of Ebewe Pharma's products that are a vital part of treating a range of cancers.
Dr Daniel Vasella, Novartis' chairman and chief executive officer, noted the deal will strengthen the company's pipeline with a number of planned launches.
He added the inclusion of the treatments fits into the business' strategy to help sufferers around the world receive therapies.
"These medicines will remain the backbone of multi-drug treatments in the fight against cancer, one of the world's leading causes of death," stated Dr Vasella.
Meanwhile, Novartis has gained exclusive worldwide rights to develop and commercialise QMF149 with an inhaled corticosteroid mometasone from Schering-Plough's portfolio.
QMF149 is a fixed-combination of the company's investigational QAB149 (indacaterol).Other news stories from 21/05/2009
Read more in the Zenopa News Archive
How this news is generated
|
